<?xml version="1.0" encoding="UTF-8"?>
<p>The CD4bs on gp120 appear to be the most important target of protein- and peptide-based HIV inactivators. Most of those that are under preclinical and clinical development target CD4bs alone, CD4bs plus co-receptor-binding site (CoRbs) on gp120, or CD4bs plus some region(s) in the HIV-1 gp41 (
 <xref ref-type="fig" rid="F2">Figure 2C</xref>). These strategies can also be applied to design and develop virus inactivators against other enveloped viruses, such as those described below.
</p>
